Feasibility and Safety of PD-1 Blockades Among Elderly Patients with Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Study

Autor: Bai M, Wang WX, Deng T, Duan JJ, Ba Y

Publikováno v: Drug Design, Development and Therapy, Vol Volume 18, Pp 4135-4151 (2024)

Ming Bai,1,* Wei-Xue Wang,1,2,* Ting Deng,1 Jing-Jing Duan,1 Yi Ba1,3 1Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of

Externí odkaz: https://doaj.org/article/353b7244833f4f6d970e296b0af2ec44

Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study

Autor: Dou XJ, Ma RY, Ren DW, Liu Q, Yan P

Publikováno v: Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 29-40 (2024)

Xue-Jun Dou,1,* Run-Yang Ma,1,* De-Wang Ren,1 Qiang Liu,2 Peng Yan3 1Department of Thoracic Surgery, Aerospace Center Hospital, Beijing, 100049, People’s Republic of China; 2Department of Thoracic Surgery, Peking University International Ho

Externí odkaz: https://doaj.org/article/e02352716d8940d59a5a94e8615c2660

Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study

Autor: Jia M, Jia JK, Xu J, Xue HZ

Publikováno v: Cancer Management and Research, Vol Volume 14, Pp 2625-2638 (2022)

Meng Jia, Jiang-Kun Jia, Jian Xu, Huan-Zhou Xue Department of Hepatobiliary Surgery, Henan Provincial People’s Hospital, Zhengzhou, 450003, People’s Republic of ChinaCorrespondence: Huan-Zhou Xue, Department of Hepatobiliary Surgery of Henan Prov

Externí odkaz: https://doaj.org/article/4224c309f87e401ca3279acb8864c42f

Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications

Autor: Xuqi Sun, Qi Zhang, Jie Mei, Ziliang Yang, Minshan Chen, Tingbo Liang

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)

Abstract Background This study aimed to evaluate the efficiency and prognostic factors of lenvatinib plus programmed death 1 (PD-1) blockades in patients with advanced hepatocellular carcinoma (HCC), especially for those with tumor occupation ≥50%

Externí odkaz: https://doaj.org/article/bb7ffe55ce6c43a2bb514d68580317e0

Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns [Predictive biomarkers of response to immune checkpoint inhibitors.]

Autor: Alexandra Lespagnol, Cédric Ménard, Romain Corre, Karin Tarte, Samuel Le Sourd, Jean Mosser, Marc Pracht, Julien Edeline, Alexandra Frelau

Publikováno v: Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2018, 105 Suppl 1, pp.S80-S91. ⟨10.1016/S0007-4551(18)30393-X⟩
Bulletin du Cancer, 2018, 〈10.1016/j.bulcan.2017.10.031〉
Bulletin du Cancer, 2018, 105 Suppl 1, pp.S80-S91. ⟨10.1016/S0007-4551(18)30393-X⟩
Bulletin du Cancer, John Libbey Eurotext, 2018, ⟨10.1016/j.bulcan.2017.10.031⟩
Bulletin du Cancer, 2018, ⟨10.1016/j.bulcan.2017.10.031⟩

International audience; Les anti-PD-1 s’imposent dernièrement comme un traitement de référence dans de nombreux cancers métastatiques. Ils présentent l’avantage d’une efficacité significative doublée d’un profil de toxicité favorable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a02af89891808eb0b3aa9d0d66d3e0f
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01993658